R. Attanasio et al., GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide, J ENDOC INV, 24(4), 2001, pp. 209-216
New depot somatostatin analogs such as lanreotide-slow release (LAN) repres
ent a significant improvement in the medical treatment of acromegaly. Seven
ty-three consecutive acromegalic patients, treated by LAN, were evaluated i
n a retrospective monocentric study. Sixteen were excluded from further eva
luation due to combined treatment with dopamine agonist drugs, early LAN wi
thdrawal for persistence of headache, or gastrointestinal side-effects. Fif
ty-seven patients (aged 20-82 years, 16 males) were thus evaluated. Thirty-
two patients had been previously treated by neurosurgery (Tx) and/or radiot
herapy (Rx). After washout, LAN (30 mg) was administered im at 10-14-day in
tervals. Time intervals between injections were then individually tailored
to normalize IGF-I levels. LAN was administered for 12(6-36) [median (range
)] months. GH and IGF-I levels decreased from 13 (7-20) [median (interquart
ile)] mug/l to 3.2 (1.7-6.2) mug/l (p <0.0001) and from 780 (596-1000) mug/
l to 264 (180-530) mug/l (p <0.000001), respectively. Seven patients were r
esistant to treatment. Among the 50 sensitive patients, GH levels fell belo
w 2.5 mug/l in 52% (and below 1 mug/l in 18%), IGF-I levels normalized in 7
2% and both results were obtained in 46%. IGF-I values normalized in 87% of
patients treated every 14 days, in 100% every 21-28 days, in 69% every 10
days and in 22% every 7 days. No different control of GH/IGF-I hypersecreti
on was evidenced between patients previously treated or not by Tx and/or Rx
. Patients with the lowest basal hormonal levels and those over 55 years sh
owed greater responsiveness (both p <0.05). The maintenance of LAN schedule
up to 18 months determined a further suppression (p=0.04 for IGF-I). A red
uction of tumor size was shown in 60% of evaluated patients (6/10), HbA(1c)
slightly increased in 42% of patients and gallstones were observed in 16%.
LAN is a very effective tool in the treatment of acromegaly: its chronic a
dministration normalizes GH/IGF-I levels in most patients, shrinks the tumo
r in a high percentage of patients and seems to control hormonal hypersecre
tion as primary treatment as well as neurosurgery. ((C))2001, Editrice Kurt
is.